Sharemaestro Newsreel

Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped …

Bionano outlines $31M-$33M 2026 revenue forecast amid flow cell supply constraints

Earnings Call Insights: Bionano Genomics (BNGO) Q2 2026 MANAGEMENT VIEW * "Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers," said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding …

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts' average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The …

Elizabeth Warren Says UnitedHealth, CVS Have Too Much Control Over US Healthcare—Now She Wants to Break Up the Vertical Integration

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Sen. Elizabeth Warren (D-Mass) has criticized the vertical integration in the U.S. healthcare system, arguing that it leads to higher costs for patients and increased profits for …

Informe de resultados de Hims & Hers: ingresos del Q2 2026 superan previsiones, pero el BPA defrauda

Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America’s New Drug Manufacturing Policies?

For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and …

Why Eli Lilly Topped the Market Today

Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly › Eli …

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

Hims & Hers Health, Inc. (HIMS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. …

Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one …

3 Reasons to Sell UHS and 1 Stock to Buy Instead

3 Reasons to Sell UHS and 1 Stock to Buy Instead Shareholders of Universal Health Services would probably like to forget the past six months even happened. The stock dropped 20.7% and now trades at $168.95. This may have investors wondering how to approach …

Hims & Hers Lowers Profit Forecast, Shares Drop

Hims & Hers Health shares are down after the telehealth firm reduced the top end of its adjusted Ebitda forecast for the full year. Madison Muller reports on "Bloomberg The Close." View Comments

Hims Stock Falls on Earnings. Why a Guidance Hike Isn’t Enough.

Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading

What Is Behind Veeva Systems (VEEV) Latest Move?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Broker Signals On Veeva Systems Stock A fresh wave of brokerage opinions on Veeva Systems (VEEV) has put the stock back in focus for investors, …

Intuitive Surgical (ISRG) Just Beat Earnings. Is the Stock Still Worth Paying a Premium?

Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS of $2.80 exceeding expectations by $0.30. Despite that, the stock plunged due to mounting concerns …

Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?

Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised …

Hims Topples As Obesity Kingpin Hits A Snag On Weighty Second-Quarter Loss

Hims stock fell late Monday after its second-quarter loss came in bigger than expected, upsetting a sales beat. Continue Reading

Hims & Hers shares fall after second-quarter wider-than-expected loss

Investing.com -- Hims & Hers Health reported a wider-than-expected second-quarter loss on Monday, sending its shares down 1.5%. The company reported a loss of 37 cents per share, compared with analysts' estimate of a loss of 5 cents per share. Revenue rose 38% year …

Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops

Hims & Hers Health (NYSE:HIMS) Exceeds Q2 CY2026 Expectations But Stock Drops Telehealth company Hims & Hers Health (NYSE:HIMS) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 38.2% year on year to $753.2 million. On top of that, next …

Bionano Genomics presenta sus previsiones de ingresos para el tercer trimestre y el ejercicio 2026

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

ProKidney Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of …

Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results

Revenue of approximately $753 million, up 38% year-over-year in Q2 2026 Subscribers grew to nearly 2.9 million, up 19% year-over-year in Q2 2026 Raises full year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion and updates Adjusted EBITDA guidance to …

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

Olema Oncology Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027 Presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting Announced a clinical trial collaboration and supply agreement …

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and …

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) received UK authorization for Silver Upgrade …

Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and …

How Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform

In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for …

James P. Holland to Join Humana as Medicaid President

LOUISVILLE, Ky., August 10, 2026--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today announced that James "J.P." Holland will join the company as senior vice president and President of Medicaid, effective August 17. In this role, Holland will lead the company's growing Medicaid business, which currently serves …

Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY

During the August 6 episode of CNBC's Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors …

S&P 500 Companies' Quarterly Earnings Growth Eases Amid Healthcare Drop, Oppenheimer Says

S&P 500 companies' quarterly earnings growth rate eased from a week ago amid a drop in the healthcar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. …

Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance

On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC's Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That's the big medical technology and supply play... That was …

Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?

Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $10.1 million Shares purchased 208,359 Post-transaction shares (total) …

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Bristol Myers Squibb to build $2.3 billion Houston campus

Bristol Myers Squibb announced Monday it will build a $2.3 billion drug manufacturing campus in Houston, Texas, part of the company's broader $40 billion commitment to invest in the United States over five years. The roughly 600,000-square-foot campus will be located at Generation Park, …

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered

QuidelOrtho Corporation QDEL delivered adjusted earnings per share (EPS) of 13 cents in second-quarter 2026, up 8.3% year over year. The figure beat the Zacks Consensus Estimate by 425%. The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among …

Integer Holdings Q2 Earnings & Revenues Top Estimates, Margins Decline

Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.60 in the second quarter of 2026, up 3.2% year over year. The figure beat the Zacks Consensus Estimate by 15.9%. The adjustments include expenses related to the amortization of intangible assets and …